Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BXRX save search
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
Published: 2023-01-24 (Crawled : 14:00) - biospace.com/
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 101.98%
H: 12.58%
C: -31.86%
bx1000 for trial positive
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
Published: 2022-12-30 (Crawled : 14:00) - prnewswire.com
SILO | $2.5275 -1.27% 2.87% 54K
|
Finance and Insurance
|
| O: 59.74%
H: 0.0%
C: 0.0%
NUWE | $9.24 -6.95% -7.93% 190K
|
Manufacturing
|
| O: -19.4%
H: 0.0%
C: 0.0%
KALA | $16.54 -0.66% -1.34% 89K
|
Health Technology
|
| O: 111.55%
H: 0.0%
C: 0.0%
HOTH | $3.48 -19.07% -23.92% 7.3M
|
Health Technology
|
| O: -13.98%
H: 0.0%
C: 0.0%
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: -17.27%
H: 0.0%
C: 0.0%
global expected market
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
Published: 2022-12-08 (Crawled : 14:20) - biospace.com/
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 4.15%
H: 22.51%
C: 15.95%
bx1000 trial
Baudax Bio Announces Pricing of $5 Million Public Offering
Published: 2022-12-02 (Crawled : 20:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
| Email alert
Add to watchlist
offering
Baudax Bio Announces 1-for-40 Reverse Stock Split
Published: 2022-11-30 (Crawled : 22:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
| Email alert
Add to watchlist
Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference
Published: 2022-09-08 (Crawled : 01:00) - biospace.com/
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: -5.27%
H: 0.0%
C: 0.0%
conference
Baudax Bio Announces Closing of $6.2 Million Public Offering
Published: 2022-09-01 (Crawled : 19:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 0.82%
H: 5.6%
C: -5.05%
offering
Baudax Bio Announces Pricing of $6.2 Million Public Offering - Aug 30, 2022
Published: 2022-08-30 (Crawled : 06:00) - biospace.com/
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: -43.34%
H: 0.0%
C: 0.0%
offering
Baudax Bio Announces Pricing of $6.2 Million Public Offering
Published: 2022-08-30 (Crawled : 03:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: -43.34%
H: 0.0%
C: 0.0%
offering
Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain
Published: 2022-08-22 (Crawled : 14:00) - biospace.com/
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 0.07%
H: 1.81%
C: -6.25%
anjeso treatment patent for application
Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth
Published: 2022-07-06 (Crawled : 13:00) - biospace.com/
CPB | $50.9 -0.78% 0.2% 1.8M
|
Consumer Non-Durables
|
| O: -0.53%
H: 0.0%
C: 0.0%
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 2.86%
H: 1.44%
C: -1.17%
growth
Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: 2022-05-17 (Crawled : 00:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: -28.51%
H: 1.56%
C: -3.81%
offering nasdaq
Alkermes plc Reports First Quarter 2022 Financial Results
Published: 2022-04-27 (Crawled : 14:20) - biospace.com/
JNJ | $163.61 0.13% 0.22% 4.7M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
BIIB A | $285.45 -2.05% -2.05% 500K
|
Health Technology
|
| O: 0.3%
H: 1.11%
C: -0.33%
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 0.67%
H: 4.05%
C: 3.38%
ALKS | $26.79 -1.44% -1.46% 960K
|
Health Technology
|
| O: 13.01%
H: 2.29%
C: -0.95%
results
Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 3.09%
H: 5.69%
C: 4.19%
financial results report results
Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference
Published: 2022-03-10 (Crawled : 14:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 6.98%
H: 0.0%
C: -2.17%
health thc conference
Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery
Published: 2022-03-08 (Crawled : 22:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 1.27%
H: 2.49%
C: 1.25%
anjeso trial
Baudax Bio Regains Compliance with NASDAQ Listing Requirements
Published: 2022-03-07 (Crawled : 14:30) - biospace.com/
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 1.74%
H: 0.26%
C: -9.71%
nasdaq
Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®
Published: 2022-03-02 (Crawled : 13:30) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: 0.0%
H: 0.53%
C: -1.58%
anjeso ces patent
Baudax Bio Announces Pricing of $10.0 Million Public Offering - Feb 25, 2022
Published: 2022-02-25 (Crawled : 09:00) - biospace.com/
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: -46.37%
H: 0.0%
C: 0.0%
offering ces
Baudax Bio Announces Pricing of $10.0 Million Public Offering
Published: 2022-02-25 (Crawled : 05:00) - globenewswire.com
BXRX | $3.25 -4.69% -6.07% 170K
|
Health Technology
|
| O: -46.37%
H: 0.0%
C: 0.0%
offering ces publication
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
CZOO | $0.2001 -16.63% 1864.02% 3.3M
|
AVRO | $1.69 93.7% 54.08% 38M
|
Health Technology
CELZ | $1.04 101.04% 50.26% 140M
|
WETG | $0.65 58.54% 37.88% 27M
|
GFAI | $0.5408 58.36% 36.88% 89M
|
KPRX | $6.94 52.53% 34.15% 36M
|
Manufacturing
PRFX | $0.7236 44.72% 30.07% 14M
|
Health Technology
BJDX | $0.64 37.16% 23.51% 2.8M
|
SOUN 4 | $4.63 28.61% 22.08% 62M
|
THCH | $5.3 26.19% 19.69% 750K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.